TIDMABC

RNS Number : 2712Y

ABCAM Plc

01 March 2017

 
 For immediate release   01 March 2017 
 

ABCAM PLC

("Abcam" or "Company")

Total Voting Rights - Voting Rights and Capital

In conformity with the Disclosure Rules and Transparency Rules, provision 5.6.1, the Company notifies the market of the following:

The Company's issued share capital consists of 203,617,303 Ordinary Shares of 0.2p each with voting rights. The Company does not hold any shares in Treasury.

The above figure of 203,617,303 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

Date of Notification: 01 March 2017

For further information please contact:

 
                                          + 44 (0) 1223 
Abcam                                           696 000 
Suzanne Smith, Company Secretary 
 
J.P.Morgan Cazenove - Nominated Adviser     + 44 (0) 20 
 & Corporate Broker                           7742 4000 
James Mitford / Chris Cargill 
 
  FTI Consulting 
  Ben Atwell / Brett Pollard / Natalie      +44 (0) 20 
  Garland-Collins                           3727 1000 
 
 
 

Notes to Editors

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.

By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Abcam's twelve locations are in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com and www.abcamplc.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRUGUPUWUPMGQG

(END) Dow Jones Newswires

March 01, 2017 11:05 ET (16:05 GMT)

Abcam (LSE:ABC)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Abcam Charts.
Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Abcam Charts.